Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T17:05:30.971Z.
Calculation as of: 2026-10-06T17:05:30.971Z.
Quote observation: 2026-10-06T17:05:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: cc8bc0f3c1d6793fd8eee0ad66748b6583cc3e3afc130d7083cfc2a78972af23
PEG RATIO
N/A
Market Cap
$2.42B
PEG Ratio
N/A
TTM Avg
0.32
3Y Avg
0.27
5Y Avg
0.27
Market Cap
$2.30B
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | $2.37B | N/A | N/A | N/A | N/A |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.39B | N/A | N/A | N/A | N/A |
| Clover Health Investments, Corp. (CLOV)vs › | $2.40B | N/A | N/A | N/A | N/A |
| Nurix Therapeutics, Inc. (NRIX)vs › | $2.34B | N/A | N/A | N/A | N/A |
| Liquidia Corporation (LQDA)vs › | $2.33B | N/A | N/A | N/A | N/A |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.42B | N/A | N/A | N/A | N/A |
| Supernus Pharmaceuticals, Inc. (SUPN)vs › | $2.42B | N/A | 0.32 | 0.27 | 0.27 |
| Disc Medicine, Inc. (IRON)vs › | $2.44B | N/A | N/A | N/A | N/A |
| Harmony Biosciences Holdings, Inc. (HRMY)vs › | $2.30B | N/A | N/A | N/A | N/A |
| Maravai LifeSciences Holdings, Inc. (MRVI)vs › | $2.28B | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
14.6
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
